Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$0.62
-7.2%
$0.74
$0.53
$7.11
$100.33M0.242.61 million shs1.95 million shs
Metacrine, Inc. stock logo
MTCR
Metacrine
$0.58
$0.57
$0.30
$0.59
$24.75M-0.73225,834 shs83,889 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.38
-6.1%
$1.44
$1.10
$16.10
$84.71M1.351.12 million shs561,209 shs
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$1.34
-8.2%
$1.32
$1.01
$8.87
$96.42M1.611.57 million shs1.02 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
0.00%+1.87%+4.31%-58.39%-90.28%
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00%0.00%0.00%0.00%0.00%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
0.00%-15.34%+0.73%-10.39%-88.27%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
0.00%-11.84%+6.35%-24.29%-86.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
4.6515 of 5 stars
4.13.00.03.43.80.81.9
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
4.3096 of 5 stars
3.04.00.04.73.41.70.6
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
2.3112 of 5 stars
3.22.00.00.03.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
2.13
Hold$4.78671.51% Upside
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00
N/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2.00
Hold$13.31864.67% Upside
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
2.44
Hold$8.24515.26% Upside

Current Analyst Ratings Breakdown

Latest MTCR, IRWD, PLRX, and ZNTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
5/15/2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/16/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/15/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$7.00 ➝ $1.00
4/15/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$8.00 ➝ $0.70
4/14/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$3.00 ➝ $1.00
4/14/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/28/2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
3/27/2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/18/2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/17/2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$317.68M0.32N/AN/A($2.21) per share-0.28
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/A$1.36 per shareN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M53.62N/AN/A$7.91 per share0.17
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$26.87M3.59N/AN/A$6.18 per share0.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-$1.00B-$0.20N/A2.48N/A-0.65%-0.96%0.74%8/6/2025 (Estimated)
Metacrine, Inc. stock logo
MTCR
Metacrine
-$62.21M-$1.03N/AN/AN/A-84.88%-59.33%N/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$161.34M-$3.61N/AN/AN/AN/A-48.91%-41.09%8/6/2025 (Estimated)
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-$292.19M-$3.13N/AN/AN/AN/A-43.91%-34.96%8/8/2025 (Estimated)

Latest MTCR, IRWD, PLRX, and ZNTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-$0.67-$0.67N/A-$0.67N/AN/A
5/7/2025Q1 2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million
3/26/2025Q4 2024
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-$0.75-$0.66+$0.09-$0.66N/A$26.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
3.62
3.62
Metacrine, Inc. stock logo
MTCR
Metacrine
0.34
12.15
12.15
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
0.09
10.26
10.26
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/A
7.29
7.29

Institutional Ownership

CompanyInstitutional Ownership
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
Metacrine, Inc. stock logo
MTCR
Metacrine
37.72%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
12.70%
Metacrine, Inc. stock logo
MTCR
Metacrine
13.80%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
8.00%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
220161.82 million139.38 millionOptionable
Metacrine, Inc. stock logo
MTCR
Metacrine
1042.57 million36.70 millionNot Optionable
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.39 million56.96 millionOptionable
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
16071.95 million68.70 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ironwood Pharmaceuticals stock logo

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.62 -0.05 (-7.24%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$0.68 +0.06 (+9.52%)
As of 06/13/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Metacrine stock logo

Metacrine NASDAQ:MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.38 -0.09 (-6.12%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.40 +0.02 (+1.09%)
As of 06/13/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Zentalis Pharmaceuticals stock logo

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.34 -0.12 (-8.22%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.38 +0.03 (+2.61%)
As of 06/13/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.